VisiRad™ computer vision helps radiologists see lung cancer in medical imaging. Through the power of deep learning and clinical expertise.
IMIDEX is an AI company dedicated to saving lives from lung cancer. Our computer vision algorithms provide a second set of eyes for radiologist to help identify lung cancer at an earlier stage when survival is more likely. It is conducting incidental nodule detection studies with health care providers to demonstrate the clinical performance and impact of our flagship product, VisiRad.
What makes VisiRad different? Other solutions may base their models on x-ray findings alone, where the error rate can be 20-50%. Even as the solution gains more information and “learns” about diagnostic similarities between cases, it is still based on that intrinsic error rate. It may not be able to exceed that rate ats it continues to base its model on flawed data.
VisiRad takes a different approach. Our model is based on a growing contributory database consortium using longitudinal outcomes from CT Scans to pathology reports where the error rate is less than 5%. Combined with our computer vision technology and advanced machine learning, this more accurate data will lead to a new standard of care based on superior diagnostic accuracy.
VisiRad is available for research purposes only. It is not for sale for clinical use.
Laurel Bridge Software, Inc.
Provider of imaging software solutions that enables health systems to orchestrate their complex medical imaging workflows.
Laurel Bridge Software, Inc., a provider of imaging software solutions that enables health systems to orchestrate their complex medical imaging workflows, announced that IMIDEX, Inc., an Artificial Intelligence (AI) solution provider focused on lung cancer, has selected its Compass™ Routing Workflow Manager and Exodus™ Migration and Consolidation Controller to facilitate a retrospective, multi-center clinical study for the detection of incidental lung nodules using their computer-aided detection application VisiRad™.
The detection of lung nodules on chest radiographs is challenging. Detection sensitivities in clinical practice range between 30-70%. VisiRad aims to provide a second set of eyes to increase the sensitivity of lung nodule detection to help identify lung cancers at an earlier stage.
Chest radiographs are the most common radiological procedure in the world and provide an enormous opportunity for the detection of lung nodules many of which are malignant. With approximately half of lung cancers diagnosed at Stage IV, there is a significant opportunity to enhance earlier lung cancer detection.
“As leaders in AI applications in lung cancer, collaborating with Laurel Bridge was an easy decision, and their team has exceeded our expectations. IMIDEX is dedicated to the continued advancement of our computerized vision technology to improve outcomes in lung cancer” adds Richard Vlasimsky, CEO of IMIDEX.
To expedite IMIDEX’s ongoing clinical studies with VisiRad™, Laurel Bridge’s Exodus™ migration application is implemented at multiple health facilities. To protect patient privacy, the accession numbers of confirmed lung cancer patients are fed to Exodus so it can capture and anonymize all relevant studies before exporting them to the company’s Compass™ application. Compass securely routes the image data to VisiRad’s cloud server to execute the clinical validation studies and evaluate the study endpoints. The results of the studies will serve as evidence for FDA 510k regulatory submission. VisiRad is for research purposes only pending FDA clearance.
“We are proud and excited that our solutions are being used on the front lines in the ongoing fight against lung cancer,” states Jeff Blair, President of Laurel Bridge. “With the proliferation of medical imaging AI algorithms, our mission has expanded to help put these life-saving applications into the hands of radiologists by facilitating the training and development of these algorithms.”
Learn more by visiting www.LaurelBridge.com.
Society for Imaging Informatics in Medicine
The Society for Imaging Informatics in Medicine (SIIM) is the leading healthcare professional organization for those interested in the current and future use of informatics in medical imaging. The society’s mission is to advance medical imaging informatics across the enterprise through education, research, and innovation in a multi-disciplinary community.
SIIM’s strategic direction places a strong emphasis on enterprise imaging, which is defined as a set of strategies, initiatives and workflows implemented across a healthcare enterprise to consistently and optimally capture, index, manage, store, distribute, view, exchange, and analyze all clinical imaging and multimedia content to enhance the electronic health record.
SIIM is committed to the development of imaging informatics professionals. Our multidisciplinary audience and members are imaging informatics professionals – Physicians, PACS Administrators, C-Level Administrators, Clinical System Managers, Engineers, Developers, Enterprise Architects, IT Directors/Managers, Researchers, Scientists, and Industry Vendors – globally to help improve the quality, safety, and efficiency of healthcare.